U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07058454) titled 'Multicenter Prospective Observational Study of Cardiotoxicity in Patients Receiving Targeted Cancer Therapies' on June 30.
Brief Summary: This study will prospectively monitor cancer patients receiving chemotherapy (including molecular targeted therapies) for cardiovascular adverse events using biomarkers and imaging. The goal is to develop a predictive model for major adverse cardiovascular events (MACE) in this population by integrating both local factors (e.g. central venous catheter-related thrombosis) and systemic factors (e.g. age, comorbidities, genetic predisposition). An active surveillance system employing periodic cardiac...